Management of IRVAN syndrome with observation.
A 7-year-old girl with IRVAN (idiopathic retinal vasculitis, aneurysms, and neuroretinitis) syndrome was monitored for 9 years. The patient had symmetric multiple aneurysmal dilations, retinal vasculitis, and severe hard exudation in the macula bilaterally. Long-term visual acuity in her untreated right eye was 20/25. In the left eye, treated with laser panretinal photocoagulation and intravitreal vascular endothelial growth factor inhibitor therapy, visual acuity decreased to 20/200 from macular hard exudates and central fibrovascular tissue. Observation is a consideration in IRVAN syndrome if the vision remains good with hard exudation.
Madhi
M
Basha
Gary C
GC
Brown
Geremie
G
Palombaro
Carol L
CL
Shields
Jerry A
JA
Shields
D000284:Administration, Oral; D000783:Aneurysm / Q000175:diagnosis / Q000628:therapy*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002648:Child; D003131:Combined Modality Therapy; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D019370:Observation / Q000379:methods*; D011241:Prednisone / Q000627:therapeutic use; D031300:Retinal Vasculitis / Q000175:diagnosis / Q000628:therapy*; D012171:Retinal Vessels / Q000473:pathology*; D012173:Retinitis / Q000175:diagnosis / Q000628:therapy*; D013577:Syndrome; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000068258:Bevacizumab; D011241:Prednisone